We discuss the results of the phase III EXTREME (Erbitux in First-Line Treatment of
Recurrent or Metastatic Head and Neck Cancer) trial. In this study, 442 untreated patients …

The Head and Neck Squamous Cell Cancer (HNSCC) is the most common type of head and
neck cancer (more than 90%), and all over the world more than a half million people have …

Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab [a
monoclonal antibody targeting epidermal growth factor receptor (EGFR)] has been shown to …

6069 Background: In this randomized phase II trial, we investigated the efficacy and safety of
cetuximab in induction chemotherapy and followed by concurrent chemoradiotherapy …

Head and neck cancer is a challenging disease. The treatment is quite complex and
significant toxicity is seen with the combination of chemotherapy, radiation therapy and …

The administration of Cetuximab in combination with radiotherapy and chemotherapy has
shown clear survival improvements within the locally advanced and the relapsed/metastatic …

Abstract Treatment options for locally advanced squamous cell carcinoma of the head and
neck (SCCHN) include either surgical resection followed by radiation or chemoradiation, or …

16504 Background: C is an IgG1 chimerized, monoclonal antibody that binds specifically to
the epidermal growth factor receptor, which is expressed in 90–100% of HNC. We …

Abstract Background: Cetuximab (Erbitux) is the only new medical therapy for locally and
regionally advanced SCCHN to be licensed in industrialized countries in the past 15 years …

Purpose This multicenter phase II study was undertaken to define the efficacy and safety of
cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal …